BioElectronics Corp. is studying the impact of its RecoveryRx device on postoperative pain management and recovery with the goal of moving toward regulatory clearance.
Here's what you should know.
1. The study will randomly assign 40 patients who are already scheduled for total knee arthroplasty surgery to receive an active device or placebo device.
2. Completion of the study is slated for December 2018.
3. A BioElectronics distributor is managing the study at the New Mazloum Hospital in Tripoli, Lebanon.
4. "This study will help us gain regulatory clearance and allow for marketing as the standard of care following joint replacement surgeries," said Ian Rawe, PhD, director of clinical research at BioElectronics.